New phase 3 data indicate that Takeda’s investigational orexin agonist, oveporexton, significantly improves daily functioning, cognition, and nighttime sleep in patients with narcolepsy type 1.
UCLA research on postmortem brains and animal models challenges the single-cause model of narcolepsy with cataplexy.
Samples from deceased brain donors reveal specific T-cells that can target orexin/hypocretin-expressing cells.
New research reveals how orexin deficiency may paradoxically improve glymphatic function when NT1 patients are awake.
A phase 3 trial is underway to evaluate the drug's efficacy and safety in adults with IH, with enrollment expected to complete by the end of 2025.
A new study found that 85% of active duty servicemen and servicewomen have sleep disorders.
An experienced non-profit leader and author is appointed to the first-ever professional staff role for the foundation.